The results conclude that Nrf2-mediated antioxidant enzyme and mitochondrial dynamic are the targets of Rhodiola, which may be a potential treatment to prevent cardiac event for T2DM and MS patients. The gene discussed is NFE2L2; the disease is myeloid sarcoma.